Towards a translational computational model of allergen challenge in mild asthma to support clinical development of an intranasal administration of a bacterial lysate

Abstract

Given the high societal and individual burden of asthma, there is an immediate need for novel therapeutic approaches. The intranasal administration of the bacterial lysate OM-85 (historically used to prevent respiratory infections) is currently investigated to treat asthma due to its potential direct impact on immune regulatory networks in the airway mucosa. The protective efficacy and the mechanism of action of intranasal OM-85 have been robustly demonstrated in a variety of preclinical mouse asthma models.